MedTrace Logo

A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma

NCT03739320 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2018-11-13

No results posted yet for this study

Summary

Daily physical activity in adult patients with asthma remains overlooked. Limited evidence demonstrates reduced levels of daily physical activity in asthma populations but studies examining the potential effect of available therapies are missing. This study aims to investigate the overall levels of daily physical activity in patients with severe eosinophilic asthma and whether anti-interleukin-5 therapy with mepolizumab, on top of existing, maximal, and optimised asthma treatment, may improve patient's daily physical activity.

Conditions

  • Severe Eosinophilic Asthma

Interventions

DRUG

Mepolizumab 100 MG Injection [Nucala]

100 milligrams subcutaneously once every 4 weeks

Sponsors & Collaborators

  • Sotiria General Hospital

    lead OTHER

Principal Investigators

  • Marios Panagiotou, MD · Sotiria General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-11
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03739320 on ClinicalTrials.gov